Summary
Fish oil (Omega-3 fatty acids) has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Sarcopenia. ClinicalTrials.gov lists 8 registered trials linking Fish oil (Omega-3 fatty acids) to Sarcopenia: 1 is currently recruiting; 6 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 1 (NCT02103842). The largest enrolment is 150 participants (NCT06494566). Registration activity spans 2014 to 2024. No published literature item is linked to Fish oil (Omega-3 fatty acids) and Sarcopenia in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Sarcopenia ranks 82 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 25.0 (trials 20.0, literature 0.0, tier 5, approved bonus 0.0) |
| Registered trials | 8 total: 1 recruiting, 0 active / not yet recruiting, 6 completed, 1 other |
| Linked publications | 0 |
| Agent type | Supplement |
| Development stage (any indication) | Preclinical |
| Mechanism / class | Reversing decline in aging muscles: expected trends, impacts and remedies · Halma M, Marik P, Varon J, Tuszynski J · 2025 |
| Data sources | OSMF Chronic Disease Review |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT02103842 | Omega-3 Fatty Acids to Combat Sarcopenia 2014 | completed | Phase 1 | 24 |
| NCT06494566 | Omega-3 Supplementation After Surgical Treatment of Obesity 2019 | completed | Early Phase 1 | 150 |
| NCT04772040 | Impact of Fish Oil Dose on Tissue Content and Function 2021 | completed | Not applicable | 28 |
| NCT02617511 | Omega-3 Supplementation and Resistance Training 2015 | completed | Not applicable | 24 |
| NCT02779868 | Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy 2016 | completed | Not applicable | 40 |
| NCT03598413 | PeRioperative Omega Three and the Effect on ImmuNity 2018 | completed | Not applicable | 40 |
| NCT05862779 | Effects of Omega-3 and Whey Protein Supplementation on Lean Mass in Older Adults 2024 | recruiting | Not applicable | 80 |
| NCT03462771 | Dietary Supplementation With Omega-3 Fatty Acid in Muscle Response 2018 | status unknown | Not applicable | 30 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: Reversing decline in aging muscles: expected trends, impacts and remedies · Halma M, Marik P, Varon J, Tuszynski J · 2025.
OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Fish oil (Omega-3 fatty acids) approved for Sarcopenia?
Fish oil (Omega-3 fatty acids) has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Sarcopenia. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Fish oil (Omega-3 fatty acids) in clinical trials for Sarcopenia?
ClinicalTrials.gov lists 8 registered trials linking Fish oil (Omega-3 fatty acids) to Sarcopenia: 1 is currently recruiting; 6 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 1 (NCT02103842). The largest enrolment is 150 participants (NCT06494566). Registration activity spans 2014 to 2024.
What does the evidence show for Fish oil (Omega-3 fatty acids) in Sarcopenia?
Fish oil (Omega-3 fatty acids) has 6 completed registered trials for Sarcopenia but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.